• Something wrong with this record ?

Long-term Efficacy and Safety of Enzalutamide Monotherapy in Hormone-naïve Prostate Cancer: 1- and 2-Year Open-label Follow-up Results

B. Tombal, M. Borre, P. Rathenborg, P. Werbrouck, H. Van Poppel, A. Heidenreich, P. Iversen, J. Braeckman, J. Heracek, E. Baskin-Bey, T. Ouatas, F. Perabo, D. Phung, B. Baron, M. Hirmand, MR. Smith,

. 2015 ; 68 (5) : 787-94. [pub] 20150214

Language English Country Switzerland

Document type Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc16028487

BACKGROUND: Enzalutamide is an androgen receptor inhibitor with a demonstrated overall survival benefit in metastatic castration-resistant prostate cancer. A phase 2 study of enzalutamide monotherapy in patients with hormone-naïve prostate cancer (HNPC) showed a high response rate for the prespecified primary endpoint (ie, prostate-specific antigen [PSA] response at week 25), regardless of metastases at baseline, and favorable tolerability. OBJECTIVE: To determine the long-term efficacy and safety of enzalutamide monotherapy at 1 and 2 yr. DESIGN, SETTING, AND PARTICIPANTS: Open-label, single-arm study in patients with HNPC and noncastrate testosterone (≥230 ng/dl). INTERVENTION: Oral enzalutamide 160mg/d until disease progression or unacceptable toxicity. OUTCOME MEASUREMENTS AND ANALYSIS: PSA response (≥80% decline from baseline) assessed at 1 yr (49 wk) and 2 yr (97 wk). RESULTS AND LIMITATIONS: The median (range) age was 73 (48-86) yr and 26 patients (39%) presented with metastases at study entry. Of 67 patients enrolled, 45 (67%) remained on enzalutamide at week 97. For patients remaining on therapy, the PSA response rate at week 97 was 100% (95% confidence interval 92-100%). Of 26 patients with metastases at baseline, 13 (50%) had a complete and four (15.4%) had a partial response as best overall tumor response up to 97 wk on treatment. There was overall maintenance of total-body bone mineral density (BMD) and moderate changes in lean and fat body mass at 49 and 97 wk. The most common adverse events were gynecomastia, nipple pain, fatigue, and hot flushes. The study limitations include lack of a control group and of endocrine, glycemic, and lipid data at 97 wk. CONCLUSIONS: Long-term enzalutamide monotherapy in men with noncastrate HNPC is associated with large sustained reductions in PSA, signals indicating a favorable tumor response, and favorable safety/tolerability profile, with relatively small negative effects on total-body BMD. PATIENT SUMMARY: In this long-term follow-up of the efficacy and safety of enzalutamide monotherapy in patients with hormone-naïve prostate cancer, enzalutamide maintained long-term reductions in prostate-specific antigen, with a minimal impact on total-body bone mineral density. TRIAL REGISTRATION: NCT01302041.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16028487
003      
CZ-PrNML
005      
20161021121754.0
007      
ta
008      
161005s2015 sz f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.eururo.2015.01.027 $2 doi
024    7_
$a 10.1016/j.eururo.2015.01.027 $2 doi
035    __
$a (PubMed)25687533
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Tombal, Bertrand $u Institut de Recherche Clinique, Université Catholique de Louvain, Brussels, Belgium. Electronic address: bertrand.tombal@uclouvain.be.
245    10
$a Long-term Efficacy and Safety of Enzalutamide Monotherapy in Hormone-naïve Prostate Cancer: 1- and 2-Year Open-label Follow-up Results / $c B. Tombal, M. Borre, P. Rathenborg, P. Werbrouck, H. Van Poppel, A. Heidenreich, P. Iversen, J. Braeckman, J. Heracek, E. Baskin-Bey, T. Ouatas, F. Perabo, D. Phung, B. Baron, M. Hirmand, MR. Smith,
520    9_
$a BACKGROUND: Enzalutamide is an androgen receptor inhibitor with a demonstrated overall survival benefit in metastatic castration-resistant prostate cancer. A phase 2 study of enzalutamide monotherapy in patients with hormone-naïve prostate cancer (HNPC) showed a high response rate for the prespecified primary endpoint (ie, prostate-specific antigen [PSA] response at week 25), regardless of metastases at baseline, and favorable tolerability. OBJECTIVE: To determine the long-term efficacy and safety of enzalutamide monotherapy at 1 and 2 yr. DESIGN, SETTING, AND PARTICIPANTS: Open-label, single-arm study in patients with HNPC and noncastrate testosterone (≥230 ng/dl). INTERVENTION: Oral enzalutamide 160mg/d until disease progression or unacceptable toxicity. OUTCOME MEASUREMENTS AND ANALYSIS: PSA response (≥80% decline from baseline) assessed at 1 yr (49 wk) and 2 yr (97 wk). RESULTS AND LIMITATIONS: The median (range) age was 73 (48-86) yr and 26 patients (39%) presented with metastases at study entry. Of 67 patients enrolled, 45 (67%) remained on enzalutamide at week 97. For patients remaining on therapy, the PSA response rate at week 97 was 100% (95% confidence interval 92-100%). Of 26 patients with metastases at baseline, 13 (50%) had a complete and four (15.4%) had a partial response as best overall tumor response up to 97 wk on treatment. There was overall maintenance of total-body bone mineral density (BMD) and moderate changes in lean and fat body mass at 49 and 97 wk. The most common adverse events were gynecomastia, nipple pain, fatigue, and hot flushes. The study limitations include lack of a control group and of endocrine, glycemic, and lipid data at 97 wk. CONCLUSIONS: Long-term enzalutamide monotherapy in men with noncastrate HNPC is associated with large sustained reductions in PSA, signals indicating a favorable tumor response, and favorable safety/tolerability profile, with relatively small negative effects on total-body BMD. PATIENT SUMMARY: In this long-term follow-up of the efficacy and safety of enzalutamide monotherapy in patients with hormone-naïve prostate cancer, enzalutamide maintained long-term reductions in prostate-specific antigen, with a minimal impact on total-body bone mineral density. TRIAL REGISTRATION: NCT01302041.
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a antagonisté androgenních receptorů $x terapeutické užití $7 D059002
650    _2
$a hormonální protinádorové látky $x terapeutické užití $7 D018931
650    _2
$a adjuvantní chemoterapie $7 D017024
650    _2
$a následné studie $7 D005500
650    _2
$a lidé $7 D006801
650    _2
$a kalikreiny $x krev $7 D007610
650    _2
$a longitudinální studie $7 D008137
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a lokální recidiva nádoru $x krev $7 D009364
650    _2
$a fenylthiohydantoin $x analogy a deriváty $x terapeutické užití $7 D010669
650    _2
$a prostatický specifický antigen $x krev $7 D017430
650    12
$a prostatektomie $7 D011468
650    _2
$a nádory prostaty $x farmakoterapie $x patologie $7 D011471
650    _2
$a výsledek terapie $7 D016896
655    _2
$a klinické zkoušky, fáze II $7 D017427
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Borre, Michael $u Aarhus University Hospital, Aarhus, Denmark.
700    1_
$a Rathenborg, Per $u Herlev Hospital, Herlev, Denmark.
700    1_
$a Werbrouck, Patrick $u AZ Groeninge Kortrijk, Kortrijk, Belgium.
700    1_
$a Van Poppel, Hendrik $u UZ Leuven, Leuven, Belgium.
700    1_
$a Heidenreich, Axel $u Klinik und Poliklinik für Urologie, RWTH University Aachen, Aachen, Germany.
700    1_
$a Iversen, Peter $u Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
700    1_
$a Braeckman, Johan $u UZ Brussel, Brussels, Belgium.
700    1_
$a Heracek, Jiri $u Univerzita Karlova v Praze, Prague, Czech Republic.
700    1_
$a Baskin-Bey, Edwina $u Astellas Pharma Global Development, Leiden, The Netherlands.
700    1_
$a Ouatas, Taoufik $u Astellas Pharma Global Development, Leiden, The Netherlands.
700    1_
$a Perabo, Frank $u Astellas Pharma Global Development, Northbrook, IL, USA.
700    1_
$a Phung, De $u Astellas Pharma Global Development, Leiden, The Netherlands.
700    1_
$a Baron, Benoit $u Astellas Pharma Global Development, Leiden, The Netherlands.
700    1_
$a Hirmand, Mohammad $u Medivation Inc., San Francisco, CA, USA.
700    1_
$a Smith, Matthew R $u Massachusetts General Hospital Cancer Center, Boston, MA, USA.
773    0_
$w MED00001669 $t European urology $x 1873-7560 $g Roč. 68, č. 5 (2015), s. 787-94
856    41
$u https://pubmed.ncbi.nlm.nih.gov/25687533 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20161005 $b ABA008
991    __
$a 20161021122203 $b ABA008
999    __
$a ok $b bmc $g 1166801 $s 953117
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2015 $b 68 $c 5 $d 787-94 $e 20150214 $i 1873-7560 $m European urology $n Eur Urol $x MED00001669
LZP    __
$a Pubmed-20161005
Back

Find record

Citation metrics

Archiving options